全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
PLOS ONE  2013 

Predictors of Raised Viral Load during Antiretroviral Therapy in Patients with and without Prior Antiretroviral Use: A Cross-Sectional Study

DOI: 10.1371/journal.pone.0071407

Full-Text   Cite this paper   Add to My Lib

Abstract:

Objectives In Lagos, Nigeria, Médecins Sans Frontières (MSF) and the Ministry of Health (MoH) commenced free antiretroviral treatment (ART) in a hospital-based clinic. We performed a cross-sectional study to compare factors associated with raised viral load between patients with (“experienced”) and without (“na?ve”) prior antiretroviral (ARV) exposure at commencement of ART at the clinic. We also examined factors influencing ARV adherence in experienced patients prior to clinic entry. Methods We included adult patients receiving ART from MSF who answered a questionnaire about previous antiretroviral use. Multivariate logistic regression was used to estimate odds ratios (OR) for raised viral load (≥1000 copies/mL). Results 1246 (96%) patients answered: 1075 (86%) reported no, and 171 (14%) some, prior ARV exposure. ARV-na?ve patients were more immunosuppressed at baseline: 65% vs 37% (p<0.001) had CD4<200; 17% vs 9% (p = 0.013) were WHO stage 4. Proportionately more experienced than na?ve patients had raised viral loads (20% vs 9%, p<0.001) on ART in the MSF/MoH clinic. Raised viral load was associated with prior ARV experience (adjusted OR = 3.74, 95%CI 2.09–6.70, p<0.001) and complete interruption of current ART (adjusted OR = 3.71, 95%CI 2.06–6.68, p<0.001). Higher CD4 at time of VL and a higher self-rated score of recent adherence were associated with lower OR of a raised viral load. Among experienced patients who missed pills before joining MSF/MoH, most common reasons were because ARVS were not affordable (58%) or available (33%), with raised viral load associated with being unsure how to take them (OR = 3.16, 95%CI 1.10–9.12, p = 0.033). Conclusions Patients previously exposed to ARVs had increased OR of raised viral load. The cost and availability of ARVs were common reasons for missing ARVs before joining the MSF/MoH clinic, and inadequate patient knowledge was associated with raised viral load.

References

[1]  Boulle A, Van Gustum G, Hilderbrand K, Cragg C, Abrahams M, et al. (2010) Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 24: 563–572.
[2]  Adams J, Patel N, Mankaryous N, Tadros M, Miller CD (2010) Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 44: 157–165.
[3]  Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, et al. (2010) Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 15: 251–258.
[4]  Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
[5]  Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21: 965–971.
[6]  Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, et al. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14: 357–366.
[7]  Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. (2001) Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15: 1181–1183.
[8]  Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36: 1100–1102.
[9]  Coetzee D, Boulle A, Hildebrand K, Asselman V, Van Cutsem G, et al. (2004) Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 18 Suppl 3S27–31.
[10]  Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K (2008) Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health 8: 265 doi: 10.1186/1471-2458-8-265.
[11]  Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, et al. (2003) Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 34: 281–288.
[12]  Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, et al. (2007) Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 45: 1492–1498.
[13]  Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, PharmAccess African Studies to Evaluate Resistance (PASER) Investigators, et al (2012) Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 12: 307–317.
[14]  Ségéral O, Limsreng S, Nouhin J, Hak C, Ngin S, et al. (2011) Short communication: three years follow-up of first-line antiretroviral therapy in Cambodia: negative impact of prior antiretroviral treatment. AIDS Res Hum Retroviruses 27: 597–603.
[15]  Stringer JS, McConnell MS, Kiarie J, Bolu O, Anekthananon T, et al. (2010) Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med 7: e1000233 doi:10.1371/journal.pmed.1000233.
[16]  El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, et al. (2011) Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One 6: e17518 doi:10.1371/journal.pone.0017518.
[17]  Chung MH, Drake AL, Richardson BA, Reddy A, Thiga J, et al. (2009) Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program. Curr HIV Res 7: 441–446.
[18]  Merten S, Kenter E, McKenzie O, Musheke M, Ntalasha H, et al. (2010) Patient-reported barriers and drivers of adherence to antiretrovirals in sub-Saharan Africa: a meta-ethnography. Trop Med Int Health 15: 16–33.
[19]  Garcia R, Badaró R, Netto EM, Silva M, Amorin FS, et al. (2006) Cross-sectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian HIV-infected patients. AIDS Res Hum Retroviruses 22: 1248–1252.
[20]  Ford N, Darder M, Spelman T, Maclean E, Mills E, et al. (2010) A. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS ONE 5: e10460 doi:10.1371/journal.pone.0010460.
[21]  WHO (2006) Antiretroviral therapy for adults and adolescents in resource-limited settings: towards universal access. Geneva: WHO. 128p.
[22]  Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, et al. (2002) Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 16: 895–9.
[23]  Bansi LK, Benzie AA, Phillips AN, Portsmouth S, UK Collaborative HIV Cohort (UK CHIC) Study, et al (2008) Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 22: 349–356.
[24]  Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 38: 1311–1316.
[25]  WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 revision. Geneva: WHO. 145 p.
[26]  van Sighem A, Zhang S, Reiss P, Gras L, van der Ende M, et al. (2008) Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy. J Acquir Immune Defic Syndr 48: 104–108.
[27]  Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, et al. (2007) Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 19: 658–665.
[28]  El-Khatib Z, Ekstrom AM, Coovadia A, Abrams EJ, Petzold M, et al. (2011) Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health 11: 88 doi:10.1186/1471-2458-11-88.
[29]  Braitstein P, Brinkhof MW, Dabis F, The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, ART Cohort Collaboration (ART-CC) groups, et al (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817–824.
[30]  Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217–224.
[31]  Burnham GM, Pariyo G, Galiwango E, Wabwire-Mangen F (2004) Discontinuation of cost sharing in Uganda. Bull WHO 82: 187–195.
[32]  Kambugu A (2012) Pre-ART HIV resistance testing in Africa: are we there yet? Lancet Infect Dis 12: 261.
[33]  El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. (2010) Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 24: 1679–1687.
[34]  Fielding KL, Charalambous S, Stenson AL, Pemba LF, Martin DJ, et al. (2008) Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 8: 93 doi:10.1186/1471-2334-8-93.
[35]  Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, et al (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283–2296.
[36]  Datay MI, Boulle A, Mant D, Yudkin P (2010) Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 54: 489–495.
[37]  Elema R, Mills C, Yun O, Lokuge K, Ssonko C, et al. (2009) Outcomes of a remote, decentralised health centre-based HIV/AIDS antiretroviral programme in Zambia, 2003–2007. J Int Assoc Physicians AIDS Care (Chic) 8: 60–67.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133